ADMA Biologics, Inc. specializes in developing and manufacturing plasma-derived products for patients with immune deficiencies, utilizing proprietary immunotechnology.

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

COM:ADMABIOLOGICS

ADMA Biologics, Inc.

Last Close

21.37

21/11 21:00

Market Cap

5.04B

Beta: -

Volume Today

2.00M

Avg: -

locale

market

industry

website

ipo date

peer of

investor of

competitor of

Metrics